RE:RE:RE:RE:RE:RE:RE:RE:RE:Suppress High Fat Diet-Induced AtherosclerosisThis is along the lines of what I was speaking about earlier, the short term in this stock is still quite uncertain. I think the $700k judgement can easily wipeout earnings in Q4, which leaves a dismal year for 2017 in terms of earnings. However, for those willing to stick out short term volatility, 2018 looks like it has a lot of room to run. Again, lower costs from running one plant, getting back on track in terms of sales and earnings and beginning to see the pipeline of new products begin to hit the market.
Assuming Q4 isnt very disappointing, I think the worst is over for the stock's share price. Although, I don't see this stock goign on a run until late spring/summer.